RT Journal Article
SR Electronic
T1 Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: a multicentre UK-based study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.24.23289022
DO 10.1101/2023.04.24.23289022
A1 Sorrell, Lexy
A1 Leta, Valentina
A1 Barnett, Anton
A1 Stevens, Kara
A1 King, Angela
A1 Inches, Jemma
A1 Kobylecki, Christopher
A1 Walker, Richard
A1 Chaudhuri, K Ray
A1 Martin, Hannah
A1 Rideout, Jane
A1 Sneyd, J Robert
A1 Campbell, Sarah
A1 Carroll, Camille
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/04/25/2023.04.24.23289022.abstract
AB Background Parkinson’s disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson’s disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.Objective To investigate clinical profiles and outcomes of people with Parkinson’s disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study.Methods A retrospective cohort study of Parkinson’s disease patients with a positive COVID-19 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson’s disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate.Results Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day mortality rate was 38.4%; male sex, increased age and frailty, Parkinson’s dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge.Conclusions This first, multicentre, UK-based study on people with Parkinson’s disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCC received the award from Parkinson’s UK (https://www.parkinsons.org.uk/) (Ref: G-2001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approvals were obtained from the University of Plymouth Faculty Research Ethics and Integrity Committee (Ref: 2269) and the Health Research Authority (IRAS ID 285686).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available on application to the sponsor with execution of an appropriate data sharing agreement.